Reduced-intensity conditioning allogeneic stem cell transplantation is a potential therapeutic approach for adults with high-risk acute lymphoblastic leukemia in remission: Results of a prospective phase 2 study

Leukemia

Volumn 23, Issue 10, 2009, Pages 1763-1770

  Cho, B S ^a   Lee, S ^a   Kim, Y J ^a   Chung, N G ^a   Eom, K S ^a   Kim, H J ^a   Min, C K ^a   Cho, S G ^a   Kim, D W ^a   Lee, J W ^a   Min, W S ^a   Kim, C C ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; FLUDARABINE; MELPHALAN; METHOTREXATE; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER MORTALITY; CANCER SURVIVAL; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; FEMALE; GRAFT SURVIVAL; HIGH RISK PATIENT; HLA MATCHING; HUMAN; INFECTION; LEUKEMIA RELAPSE; LYMPHATIC LEUKEMIA; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; SURVIVAL RATE; SURVIVAL TIME; TREATMENT INDICATION; TREATMENT RESPONSE;

EID: 70350121940     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2009.102     Document Type: Article

References (37)

1. Takeuchi J, Kyo T, Naito K, Sao H, Takahashi M, Miyawaki S et al. Induction therapy by frequent administration of doxorubicin with four other drugs, followed by intensive consolidation and maintenance therapy for adult acute lymphoblastic leukemia: The JALSG-ALL93 study. Leukemia 2002; 16: 1259-1266.
2. Kantarjian H, Thomas D, O'Brien S, Cortes J, Giles F, Jeha S et al Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer 2004; 101: 2788-2801.
3. Thomas X, Boiron JM, Huguet F, Dombret H, Bradstock K, Vey N et al Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. J Clin Oncol 2004; 22: 4075-4086.
4. Cornelissen JJ, Carston M, Kollman C, King R, Dekker AW, Lowenberg B et al. Unrelated marrow transplantation for adult patients with poor-risk acute lymphoblastic leukemia: Strong graft-versus-leukemia effect and risk factors determining outcome. Blood 2001; 97: 1572-1577.
5. Hahn T, Wall D, Camitta B, Davies S, Dillon H, Gaynon P et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute lymphoblastic leukemia in adults: An evidence-based review. Biol Blood Marrow Transplant 2006; 12 1-30.
6. Yanada M, Matsuo K, Suzuki T, Naoe T. Allogeneic hematopoietic stem cell transplantation as part of postremission therapy improves survival for adult patients with high-risk acute lymphoblastic leukemia: A metaanalysis. Cancer 2006; 106: 2657-2663.
7. Mohty M, Bay JO, Faucher C, Choufi B, Bilger K, Tournilhac O et al Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen. Blood 2003; 102: 470-476.
8. Martino R, Parody R, Fukuda T, Maertens J, Theunissen K, Ho A et al Impact of the intensity of the pretransplantation conditioning regimen in patients with prior invasive aspergillosis undergoing allogeneic hematopoietic stem cell transplantation: A retrospective survey of the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Blood 2006; 108: 2928-2936.
9. Shimoni A, Hardan I, Shem-Tov N, Yeshurun M, Yerushalmi R, Avigdor A et al. Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: The role of dose intensity. Leukemia 2006; 20: 322-328.
10. Valcarcel D, Martino R, Caballero D, Martin J, Ferra C, Nieto JB et al. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: Chronic graft-versus-host disease is the strongest factor improving survival. J Clin Oncol 2008; 26: 577-584.
11. Arnold R, Massenkeil G, Bornhauser M, Ehninger G, Beelen DW, Fauser AA et al. Nonmyeloablative stem cell transplantation in adults with high-risk ALL may be effective in early but not in advanced disease. Leukemia 2002; 16: 2423-2428.
12. Martino R, Giralt S, Caballero MD, Mackinnon S, Corradini P, Fernandez-Aviles F et al. Allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning in acute lymphoblastic leukemia: A feasibility study. Haematologica 2003; 88: 555-560.
13. Hamaki T, Kami M, Kanda Y, Yuji K, Inamoto Y, Kishi Y et al. Reduced-intensity stem-cell transplantation for adult acute lymphoblastic leukemia: A retrospective study of 33 patients. Bone Marrow Transplant 2005; 35: 549-556.
14. Mohty M, Labopin M, Tabrizzi R, Theorin N, Fauser AA, Rambaldi A et al. Reduced intensity conditioning allogeneic stem cell transplantation for adult patients with acute lymphoblastic leukemia: A retrospective study from the European Group for Blood and Marrow Transplantation. Haematologica 2008; 93: 303-306.
15. Lee S, Kim YJ, Min CK, Kim HJ, Eom KS, Kim DW et al. The effect of first-line imatinib interim therapy on the outcome of allogeneic stem cell transplantation in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 2005; 105: 3449-3457.
16. Wassmann B, Pfeifer H, Goekbuget N, Beelen DW, Beck J, Stelljes M et al. Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood 2006; 108: 1469-1477.
17. de Labarthe A, Rousselot P, Huguet-Rigal F, Delabesse E, Witz F, Maury S et al. Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: Results of the GRAAPH-2003 study. Blood 2007; 109: 1408-1413.
18. Gökbuget N, Hoelzer D, Arnold R, Böhme A, Bartram CR, Freund M et al. Treatment of Adult ALL according to protocols of the German Multicenter Study Group for Adult ALL (GMALL). Hematol Oncol Clin North Am 2000; 14: 1307-1325.
19. Kantarjian HM, O'Brien S, Smith TL, Cortes J, Giles FJ, Beran M et al Results with treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphoblastic leukemia. J Clin Oncol 2000; 18: 547-561.
20. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825-828.
21. Klein JP, Rizzo JD, Zhang MJ, Keiding N. Statistical methods for the analysis and presentation of the results of bone marrow transplants. Part 2: Regression modeling. Bone Marrow Transplant 2001; 28 1001-1011.
22. Klein JP, Rizzo JD, Zhang MJ, Keiding N. Statistical methods for the analysis and presentation of the results of bone marrow transplants. Part I: Unadjusted analysis. Bone Marrow Transplant 2001; 28 909-915.
23. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988; 16: 1141-1154.
24. Stein A, Forman SJ. Allogeneic transplantation for ALL in adults. Bone Marrow Transplant 2008; 41: 439-446.
25. Stein A, Palmer J, O'Donnell M, Kogut N, Spielberger R, Slovak ML et al. Reduced-intensity allogeneic peripheral blood stem cell transplantation for high-risk acute lymphoblastic leukemia: A potential therapeutic approach for high risk ALL patients not eligible for full intensity transplantation. Blood 2008; 112: Abstract 4321.
26. Ringden O, Labopin M, Gluckman E, Reiffers J, Vernant JP, Jouet JP et al. Graft-versus-leukemia effect in allogeneic marrow transplant recipients with acute leukemia is maintained using cyclosporin A combined with methotrexate as prophylaxis. Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 1996; 18: 921-929.
27. Zikos P, Van Lint MT, Lamparelli T, Gualandi F, Occhini D, Bregante S et al. Allogeneic hemopoietic stem cell transplantation for patients with high risk acute lymphoblastic leukemia: Favorable impact of chronic graft-versus-host disease on survival and relapse. Haematologica 1998; 83: 896-903.
28. Nordlander A, Mattsson J, Ringden O, Leblanc K, Gustafsson B, Ljungman P et al. Graft-versus-host disease is associated with a lower relapse incidence after hematopoietic stem cell transplantation in patients with acute lymphoblastic leukemia. Biol Blood Marrow Transplant 2004; 10: 195-203.
29. Lee S, Kim DW, Kim YJ, Park YH, Min CK, Lee JW et al. Influence of karyotype on outcome of allogeneic bone marrow transplantation for adults with precursor B-lineage acute lymphoblastic leukaemia in first or second remission. Br J Haematol 2002; 117: 109-118.
30. Lee S, Kim DW, Cho B, Kim YJ, Kim YL, Hwang JY et al. Risk factors for adults with Philadelphia-chromosome-positive acute lymphoblastic leukaemia in remission treated with allogeneic bone marrow transplantation: The potential of real-time quantitative reverse-transcription polymerase chain reaction. Br J Haematol 2003; 120: 145-153.
31. Lee S, Cho BS, Kim SY, Choi SM, Lee DG, Eom KS et al. Allogeneic stem cell transplantation in first complete remission enhances graft-versus-leukemia effect in adults with acute lymphoblastic leukemia: Antileukemic activity of chronic graft-versus-host disease. Biol Blood Marrow Transplant 2007; 13: 1083-1094.
32. Thomas DA, Faderl S, O'Brien S, Bueso-Ramos C, Cortes J, Garcia-Manero G et al. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer 2006; 106: 1569-1580.
33. Carpenter PA, Snyder DS, Flowers MED, Sanders JE, Gooley TA, Martin PJ et al. Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia. Blood 2007; 109: 2791-2793.
34. Slavin S, Naparstek E, Nagler A, Ackerstein A, Samuel S, Kapelushnik J et al. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. Blood 1996; 87: 2195-2204.
35. Carlens S, Aschan J, Remberger M, Dilber MS, Ringden O. Low-dose cyclosporine of short duration increases the risk of mild and moderate GVHD and reduces the risk of relapse in HLA-identical sibling marrow transplant recipients with leukaemia. Bone Marrow Transplant 1999; 24: 629-635.
36. Locatelli F, Zecca M, Rondelli R, Bonetti F, Dini G, Prete A et al Graft versus host disease prophylaxis with low-dose cyclosporine-A reduces the risk of relapse in children with acute leuekmia given HLA-identical sibling bone marrow transplantation: Results of a randomized trial. Blood 2000; 95: 1572-1579.
37. Wassmann B, Pfeifer H, Stadler M, Bornhauser M, Bug G, Scheuring UJ et al. Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphobalstic leukemia (Ph+ ALL). Blood 2005; 106: 458-463.